Floatz logo

Darolutamide

Locally Advanced Pancreatic Adenocarcinoma

OHSU Knight Cancer InstituteSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

190 Active assets in the Locally Advanced Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Ipsen
Phase 3BB

View all 50 →

Same molecule, other indications

Darolutamide is also rated in:

castration-resistant prostate carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
breast cancerDormant
BBB
Indicative ·
73 / 100
View asset →
castration-resistant prostate carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →